REGULATORY

MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake

July 30, 2026

Japan’s health ministry has asked five industry organizations, including the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), to take steps to ensure the stable supply of pharmaceuticals and medical devices following the Kumamoto earthquake.

The Ministry of Health, Labor and Welfare (MHLW) issued an administrative communication to the five organizations on July 28, saying it will monitor local supply and demand conditions for pharmaceuticals and medical devices and take any necessary measures. It also asked the organizations to provide active support if requested by the ministry.

The notice was sent to the FPMAJ, the Federation of Japan Pharmaceutical Wholesalers Association (JPWA), the Japan Federation of Medical Devices Associations, the Japan Association of Health Industry Distributors, and the Japan Industrial and Medical Gases Association.

Related Article

REGULATORY

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Philip Carrigan

A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…

By Shinya Sato

Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…